Ractigen
Ractigen is a provider of siRNA therapeutics to silence transcription repressors for the treatment of oncology, dermatology, and single-gene disorders. The companys technology is based on a discovery made at the University of California San Francisco known as RNA activation (RNAa). The companys lead candidate, RAG-1, is in the late preclinical stage and targeted for oncology. Ractigen is also developing drugs for…
Funding snapshot
About
Ractigen is a provider of siRNA therapeutics to silence transcription repressors for the treatment of oncology, dermatology, and single-gene disorders. The companys technology is based on a discovery made at the University of California San Francisco known as RNA activation (RNAa). The companys lead candidate, RAG-1, is in the late preclinical stage and targeted for oncology. Ractigen is also developing drugs for sensory, dermatology, and single-gene disorders, leveraging its RNAa platform to activate gene expression for therapeutic purposes. Founded in 2015 and headquartered in Nantong, China, Ractigen has raised approximately 17.1 million at the Series A stage with investors including Hillhouse, CCB International, Longmen Capital, SDIC, Eisai Innovation, Linkage Ventures, Xiang He Capital, and HM Venture Partners.
Business model
Nanotechnology > Nanotools > Genomics > RNA Sequencing,
Rare Diseases > Drugs > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.